<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPed</journal-id><journal-title-group><journal-title>Open Journal of Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2160-8741</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojped.2017.72012</article-id><article-id pub-id-type="publisher-id">OJPed-77014</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Duration of Preoperative External Ventricular Drain in Pediatric Posterior Fossa Tumors—Does It Matter?
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ehtesham</surname><given-names>Ghani</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ayman</surname><given-names>AlBanyan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdulrahman</surname><given-names>Sabbagh</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Maqsood</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Pediatric Neurosurgery, National Neuroscience Institute, King Fahad Medical City, Riyadh, KSA</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>ehteshamghani123@yahoo.com(EG)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>06</month><year>2017</year></pub-date><volume>07</volume><issue>02</issue><fpage>86</fpage><lpage>97</lpage><history><date date-type="received"><day>February</day>	<month>20,</month>	<year>2017</year></date><date date-type="rev-recd"><day>Accepted:</day>	<month>June</month>	<year>17,</year>	</date><date date-type="accepted"><day>June</day>	<month>20,</month>	<year>2017</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Objective: Aim of the study was to assess the duration of preoperative external ventricular drain (EVD) as a predictor for permanent cerebrospinal fluid (CSF) diversion in pediatric posterior fossa tumors. Methods: The study was conducted in the Department of Pediatric Neurosurgery, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia from January 2010 to December 2013. The data were collected retrospectively. The patients who had emergency insertion of external ventricular drain (EVD) due to hydrocephalus before the definitive posterior fossa tumor surgery were included in the study. Results: The preoperative emergency insertion of EVD was done in 38 patients with pediatric posterior fossa tumors. The patients were divided into two groups. Group A consists of those patients who had duration of preoperative EVD equal or less than 7 days. Group B includes those patients who had duration of preoperative EVD more than 7 days. Group A has 16 patients while Group B has 22 patients. The predominant clinical feature was symptoms and signs of raised intracranial pressure (ICP) only. Infection related to EVD was seen in seven patients. Ventriculoperitoneal (VP) shunt was required in 31.25% of Group A patients and 18.18% of Group B patients (p value = 0.35). Overall shunt rate was 23.68%. Conclusion: There are well known number of factors that can determine the need of permanent CSF diversion in patients with posterior fossa tumors. However, there is no effect of preoperative duration of EVD in determining the requirement of postoperative VP shunt.
 
</p></abstract><kwd-group><kwd>Posterior Fossa Tumors</kwd><kwd> External Ventricular Drain</kwd><kwd> Hydrocephalus</kwd><kwd> Ventriculoperitoneal Shunt</kwd><kwd> CSF Diversion</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The development of posterior fossa tumor surgery remains Harvey Cushing’s hallmark contribution to pediatric neurosurgery [<xref ref-type="bibr" rid="scirp.77014-ref1">1</xref>] . He was first to publish a large series of 61 patients with cerebellar medulloblastomas [<xref ref-type="bibr" rid="scirp.77014-ref2">2</xref>] . Before the era of Cushing, posterior fossa tumors were considered as inoperable and only bony decompression used to be offered. Since then, the evolution of surgical technique reflects the maturation of modern neurosurgery. Majority of patients with posterior fossa tumors have hydrocephalus at the time of presentation [<xref ref-type="bibr" rid="scirp.77014-ref3">3</xref>] . The management of hydrocephalus with posterior fossa tumors remains controversial. In recent studies, permanent postoperative cerebrospinal fluid (CSF) diversion was required in 30% - 38.7% of the patients [<xref ref-type="bibr" rid="scirp.77014-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref6">6</xref>] . However, awareness regarding factors that predict the need for CSF diversion following posterior fossa tumor surgery are essential for the surgeons during counseling, surgical planning, postoperative course and radiological monitoring [<xref ref-type="bibr" rid="scirp.77014-ref7">7</xref>] . Such factors include age of the patient, duration of history, location of the tumor, type of the tumor (solid or cystic), severity of hydrocephalus, tumor resection, CSF infection, CSF leak and pseudomeningocele [<xref ref-type="bibr" rid="scirp.77014-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref9">9</xref>] .<sup> </sup></p><p>The different surgical options are used to treat hydrocephalus. Previously some surgeons used to do separate burr hole routinely at the time of posterior fossa tumor surgery. Currently surgeons prefer CSF diversion through shunts, external ventricular drainage (EVD) or endoscopic third ventriculostomy (ETV). Each of these has its own merits and demerits. Reliability of EVD as a predictor of permanent CSF diversion is debatable. Most of the authors believe that longer the postoperative duration of EVD means permanent CSF diversion [<xref ref-type="bibr" rid="scirp.77014-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref10">10</xref>] . However, we did not find any study in the literature mentioning the preoperative duration of EVD effects shunt dependency. Therefore, we conducted this study to assess the duration of preoperative EVD in posterior fossa tumor surgery as a predictor for permanent CSF diversion.</p></sec><sec id="s2"><title>2. Methods</title><p>The study was conducted in the Department of Pediatric Neurosurgery, National Neuroscience Institute, King Fahad Medical City, Riyadh, Saudi Arabia from January 2010 to December 2013. The patients were enrolled retrospectively. The data were collected and were registered on the proforma. All the data were reviewed. Data were generated from the clinical, operative and radiological records. Categorical data were summarized as number and percentage. Continuous data was summarized as mean and standard deviation. Comparison between the groups for categorical variable was done using chi-square test or Fisher’s exact test and for continuous data student-t test or Mann Whitney u was used. Any association with p-value of less than 0.05 was considered as statistically significant. All statistical analysis was performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC).</p><p>The patients who had insertion of EVD before the definitive posterior fossa tumor surgery in pediatric age were included. All such patients presented in emergency due to severe hydrocephalus. These patients underwent emergency insertion of EVD after CT scan. Later, magnetic resonance imaging (MRI) of brain and spine were done before undergoing definitive posterior fossa tumor surgery in all patients. Most of the patients required MRI under general anesthesia. After tumor surgery, the patients were considered for challenging of EVD around on 7<sup>th</sup> postoperative day. If there were no clinical and radiological signs of hydrocephalus, EVD was removed. Otherwise, insertion of ventriculoperitoneal (VP) shunt was done.</p><p>The patients who were managed without EVD or with intraoperative insertion of EVD, who had shunt insertion before posterior fossa tumor surgery and who had surgery for recurrence were excluded from the study.</p><p>The time interval between insertion of EVD and definite tumor surgery was considered in dividing the patients in two groups. Group A consists of those patients who had duration of preoperative EVD equal or less than 7 days. Group B includes those patients who had duration of preoperative EVD more than 7 days. Different factors were studied in each group including age and sex of the patient, duration of symptoms, clinical presentation, duration of MRI after admission, location of the tumor, CSF seeding, amount of surgical resection, type of the tumor on histopathology, duration of postoperative EVD, CSF leak, pseudomeningocele, EVD related infection and VP shunt insertion. Data were analyzed and the literature was reviewed.</p></sec><sec id="s3"><title>3. Results</title><p>The preoperative emergency insertion of EVD was done in 38 pediatric patients with posterior fossa tumor (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Mean duration of preoperative EVD was 5.44 days in Group A and 13.72 days in Group B. Group A has 16 patients while Group B has 22 patients. In Group B, initially parents of three patients refused surgery and later they agreed. Mean age was 4.5 year in Group A and 5.5 year in Group B. Male to female ratio was 1:0.6 in Group A and 1:0.8 in Group B. The predominant clinical feature was symptoms an d signs of raised intracranial pressure (ICP) only (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Those were seen exclusively in 81.25% of patients in Group A and 77.27% of patients in Group B. The most of the patients presented with short duration of symptoms in both groups and had midline tumor (<xref ref-type="fig" rid="fig3">Figure 3</xref>). CSF seedings were appreciated in five patients in Group A and four patients in Group B (p value = 0.81). Gross total resection was achieved in 81.25% and 81.82% in Group A and B respectively. Medulloblastoma was the prime histopathologic diagnosis in both groups. It was followed by pilocytic astrocytoma, anaplastic ependymoma, cavernous hemangioma and Ewing’s sarcoma. CSF leak was observed in total of five patients (13.16%). It was seen in three patients in Group A and two patients in Group B (p value = 0.63). Pseudomeningocele was noted in six patients overall. It was found in two patients in Group A and four patients in Group B (p value = 0.63). Postoperatively EVD was kept in for mean of 17.44 days in Group A and 16.59 days in Group B.</p><p>Seven patients had EVD related infection (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Preoperative EVD re-</p><fig-group id="fig1"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Plain axial CT scans of 8 year old boy with posterior fossa tumor which is partially calcified (a) and associated with acute hydrocephalus (b).</title></caption><fig id ="fig1_1"><label> (b)</label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1330546x2.png"/></fig><fig id ="fig1_2"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1330546x3.png"/></fig></fig-group><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Clinical features</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1330546x4.png"/></fig><fig id="fig3"  position="float"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> Location of tumours</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1330546x5.png"/></fig><p>lated infection secondary to Klebsiella pneumoniae was seen in one patient in Group B. He did not require shunt. There were three patients in each group who had postoperative EVD related infection with 18.75% in Group A and 13.64% in Group B (p value = 0.64). In Group A, infection was caused by Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. In Group B, Klebsiella pneumoniae, Staphylococcus epidermidis and Enterobacter aerogenes were cultured from CSF. Once the infection is clear, all patients in Group A with infection and in Group B with Klebsiella pneumoniae and Staphylococcus epidermidis infection required shunt surgery. Overall, infection was seen in 18.4% of the patients. However, six patients who had infection eventually required VP shunt. VP shunt (<xref ref-type="fig" rid="fig5">Figure 5</xref>) was required in 31.25% of Group A patients and 18.18% of Group B patients (p value = 0.35). In total, shunt insertion rate was 23.68%. All the patients were followed up closely for six months. Results are shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s4"><title>4. Discussion</title><p>The posterior fossa is a limited space in the cranium. The tumors in this region usually present earlier. Posterior fossa tumors are the most common primary neoplasms in children. Such tumors require prompt decision and quick action as the most of the patients have associated hydrocephalus at presentation [<xref ref-type="bibr" rid="scirp.77014-ref3">3</xref>] . Early treatment will eventually affect the morbidity and mortality. However, there is</p><fig id="fig4"  position="float"><label><xref ref-type="fig" rid="fig4">Figure 4</xref></label><caption><title> EVD related infection (seven patients)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1330546x6.png"/></fig><fig id="fig5"  position="float"><label><xref ref-type="fig" rid="fig5">Figure 5</xref></label><caption><title> Postoperative VP shunt insertion</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1330546x7.png"/></fig><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Breakdown of the data</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >Factors</th><th align="center" valign="middle" >Group A (EVD less than 7 days) Mean = 5.44 &#177; 1.78 days</th><th align="center" valign="middle" >Group B (EVD more than 7 days) Mean = 13.72 &#177; 5.81</th><th align="center" valign="middle" >Overall Mean = 10.23 &#177; 6.14</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >Number of Patients (n)</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Age (In Months) Mean &#177; SD</td><td align="center" valign="middle" >54.19 &#177; 24.52</td><td align="center" valign="middle" >66.73 &#177; 33.57</td><td align="center" valign="middle" >61.45 &#177; 30.37</td><td align="center" valign="middle" >0.21</td></tr><tr><td align="center" valign="middle" >Sex</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male, n (%)</td><td align="center" valign="middle" >10 (62.50%)</td><td align="center" valign="middle" >12 (54.55%)</td><td align="center" valign="middle" >22 (57.89%)</td><td align="center" valign="middle" >0.62</td></tr><tr><td align="center" valign="middle" >Female, n (%)</td><td align="center" valign="middle" >6 (37.50%)</td><td align="center" valign="middle" >10 (45.45%)</td><td align="center" valign="middle" >16 (42.11%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Duration of Symptoms</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Less than 1 month, n (%)</td><td align="center" valign="middle" >10 (62.50%)</td><td align="center" valign="middle" >14 (63.64%)</td><td align="center" valign="middle" >24 (63.16%)</td><td align="center" valign="middle" >0.94</td></tr><tr><td align="center" valign="middle" >More than 1 month, n (%)</td><td align="center" valign="middle" >6 (37.50%)</td><td align="center" valign="middle" >8 (36.36%)</td><td align="center" valign="middle" >14 (36.84%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Clinical Features</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Signs of raised ICP only, n (%)</td><td align="center" valign="middle" >13 (81.25%)</td><td align="center" valign="middle" >17 (77.27%)</td><td align="center" valign="middle" >30 (78.95%)</td><td align="center" valign="middle" >0.81</td></tr><tr><td align="center" valign="middle" >Signs of raised ICP with cranial nerve deficits, n (%)</td><td align="center" valign="middle" >2 (12.50%)</td><td align="center" valign="middle" >2 (9.09%)</td><td align="center" valign="middle" >4 (10.53%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Signs of raised ICP with head enlargement or delayed milestones, n (%)</td><td align="center" valign="middle" >1 (6.25%)</td><td align="center" valign="middle" >2 (9.09%)</td><td align="center" valign="middle" >3 (7.89%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Signs of raised ICP with loss of consciousness, n (%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >1 (4.55%)</td><td align="center" valign="middle" >1 (2.63%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Duration of MRI (In Days) Mean &#177; SD</td><td align="center" valign="middle" >3.25 &#177; 1.69</td><td align="center" valign="middle" >4.41 &#177; 1.79</td><td align="center" valign="middle" >3.92 &#177; 1.82</td><td align="center" valign="middle" >0.04</td></tr><tr><td align="center" valign="middle" >Location of the Tumour</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Midline, n (%)</td><td align="center" valign="middle" >13 (81.25%)</td><td align="center" valign="middle" >18 (81.82%)</td><td align="center" valign="middle" >31 (81.58%)</td><td align="center" valign="middle" >0.96</td></tr><tr><td align="center" valign="middle" >Lateral, n (%)</td><td align="center" valign="middle" >3 (18.75%)</td><td align="center" valign="middle" >4 (18.18%)</td><td align="center" valign="middle" >7 (18.42%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CSF Seeding</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No, n (%)</td><td align="center" valign="middle" >11 (68.75%)</td><td align="center" valign="middle" >18 (81.82%)</td><td align="center" valign="middle" >29 (76.32%)</td><td align="center" valign="middle" >0.80</td></tr><tr><td align="center" valign="middle" >Yes, n (%)</td><td align="center" valign="middle" >5 (31.25%)</td><td align="center" valign="middle" >4 (18.18%)</td><td align="center" valign="middle" >9 (23.68%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Diagnosis</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Medulloblastoma, n (%)</td><td align="center" valign="middle" >8 (50.00%)</td><td align="center" valign="middle" >14 (63.64%)</td><td align="center" valign="middle" >22 (57.89%)</td><td align="center" valign="middle" >0.65</td></tr><tr><td align="center" valign="middle" >Pilocytic astrocytoma, n (%)</td><td align="center" valign="middle" >3 (18.75%)</td><td align="center" valign="middle" >5 (22.73%)</td><td align="center" valign="middle" >8 (21.05%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Anaplastic ependymoma, n (%)</td><td align="center" valign="middle" >3 (18.75%)</td><td align="center" valign="middle" >2 (9.09%)</td><td align="center" valign="middle" >5 (13.16%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ewing’s sarcoma, n (%)</td><td align="center" valign="middle" >1 (6.25%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >1 (2.63%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Cavernous haemangioma, n (%)</td><td align="center" valign="middle" >1 (6.25%)</td><td align="center" valign="middle" >1 (4.55%)</td><td align="center" valign="middle" >2 (5.26%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Surgery</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gross total, n (%)</td><td align="center" valign="middle" >13 (81.25%)</td><td align="center" valign="middle" >18 (81.82%)</td><td align="center" valign="middle" >31 (81.58%)</td><td align="center" valign="middle" >0.96</td></tr><tr><td align="center" valign="middle" >Subtotal, n (%)</td><td align="center" valign="middle" >3 (18.75%)</td><td align="center" valign="middle" >4 (18.18%)</td><td align="center" valign="middle" >7 (18.42%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CSF Leak</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No, n (%)</td><td align="center" valign="middle" >13 (81.25%)</td><td align="center" valign="middle" >20 (90.91%)</td><td align="center" valign="middle" >33 (86.84%)</td><td align="center" valign="middle" >0.63</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >Yes, n (%)</th><th align="center" valign="middle" >3 (18.75%)</th><th align="center" valign="middle" >2 (9.09%)</th><th align="center" valign="middle" >5 (13.16%)</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >Pseudomeningocele</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No, n (%)</td><td align="center" valign="middle" >14 (87.50%)</td><td align="center" valign="middle" >18 (81.82%)</td><td align="center" valign="middle" >32 (84.21%)</td><td align="center" valign="middle" >0.63</td></tr><tr><td align="center" valign="middle" >Yes, n (%)</td><td align="center" valign="middle" >2 (12.50%)</td><td align="center" valign="middle" >4 (18.18%)</td><td align="center" valign="middle" >6 (15.79%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Infection</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No, n (%)</td><td align="center" valign="middle" >13 (81.25%)</td><td align="center" valign="middle" >18 (81.82%)</td><td align="center" valign="middle" >31 (81.58%)</td><td align="center" valign="middle" >0.64</td></tr><tr><td align="center" valign="middle" >Postoperative, n (%)</td><td align="center" valign="middle" >3 (18.75%)</td><td align="center" valign="middle" >3 (13.64%)</td><td align="center" valign="middle" >6 (15.79%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Preoperative, n (%)</td><td align="center" valign="middle" >0 (0.00%)</td><td align="center" valign="middle" >1 (4.55%)</td><td align="center" valign="middle" >1 (2.63%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Insertion of VP Shunt</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >No, n (%)</td><td align="center" valign="middle" >11 (68.75%)</td><td align="center" valign="middle" >18 (81.82%)</td><td align="center" valign="middle" >29 (76.32%)</td><td align="center" valign="middle" >0.35</td></tr><tr><td align="center" valign="middle" >Yes, n (%)</td><td align="center" valign="middle" >5 (31.25%)</td><td align="center" valign="middle" >4 (18.18%)</td><td align="center" valign="middle" >9 (23.68%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Duration of Postoperative EVD Mean &#177; SD</td><td align="center" valign="middle" >17.44 &#177; 13.87</td><td align="center" valign="middle" >16.59 &#177; 17.28</td><td align="center" valign="middle" >16.95 &#177; 15.73</td><td align="center" valign="middle" >0.42</td></tr></tbody></table></table-wrap></table-wrap-group><p>no consensus on the management of hydrocephalus secondary to posterior fossa tumor [<xref ref-type="bibr" rid="scirp.77014-ref7">7</xref>] . It can be managed before, during and after posterior fossa tumor surgery [<xref ref-type="bibr" rid="scirp.77014-ref11">11</xref>] .</p><p>In 1963, Abraham and Chandy managed the hydrocephalus related to posterior fossa tumors with ventriculoatrial (VA) shunts [<xref ref-type="bibr" rid="scirp.77014-ref12">12</xref>] . This method of managing the hydrocephalus became popular. Many neurosurgeons adopted the policy of putting VP or VA shunts before the definitive posterior fossa tumor surgery to have a better operative field. It resulted in 100% of the patients having permanent shunt insertion or dependency [<xref ref-type="bibr" rid="scirp.77014-ref13">13</xref>] . In 1985, the American Society of Pediatric Neurosurgery commissioned a study to find out the best way to manage the dilemma of hydrocephalus secondary to posterior fossa tumors. Robert McLaurin made the conclusion after obtaining the data from different hospitals of North America that there was no clear evidence of having any advantage to do preoperative shunt insertion [<xref ref-type="bibr" rid="scirp.77014-ref14">14</xref>] . It is still a matter of discussion.</p><p>Management of hydrocephalus secondary to posterior fossa tumors includes insertion of EVD, ETV, shunt insertion and no treatment at all [<xref ref-type="bibr" rid="scirp.77014-ref11">11</xref>] . Some surgeons in the past preferred to place a separate burr hole routinely during the posterior fossa tumor surgery to drain the ventricles [<xref ref-type="bibr" rid="scirp.77014-ref15">15</xref>] . Ventricular tap was also used in infants with open fontanel [<xref ref-type="bibr" rid="scirp.77014-ref16">16</xref>] . Recently Ommaya reservoir was used as an alternate to EVD, VP shunt and ETV. It is associated with lesser trauma and fewer complications [<xref ref-type="bibr" rid="scirp.77014-ref17">17</xref>] . Relieving the hydrocephalus in the presence of posterior fossa tumor can cause sudden decompression. It may lead to the formation of extradural hematoma [<xref ref-type="bibr" rid="scirp.77014-ref18">18</xref>] . ETV and VP shunt are recommended as permanent treatment for hydrocephalus after posterior fossa tumor surgery [<xref ref-type="bibr" rid="scirp.77014-ref11">11</xref>] .</p><p>There are number of factors that can determine the need for CSF diversion after the surgery. All these factors are debatable. Most of the surgeons believe that age at surgery is related to postoperative CSF diversion. Younger the patient means more chance of having permanent CSF diversion after surgery [<xref ref-type="bibr" rid="scirp.77014-ref9">9</xref>] . However; some surgeons observed that mean age at diagnosis and extent of tumor resection do not affect the need for CSF diversion. It was also noted that the patients who presented with duration of symptoms less than 3 months had higher rate of postoperative CSF diversion [<xref ref-type="bibr" rid="scirp.77014-ref7">7</xref>] . It is believed that midline tumors require more shunts than laterally located tumors [<xref ref-type="bibr" rid="scirp.77014-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref9">9</xref>] .<sup> </sup>Medulloblastoma and ependymoma are more associated with postoperative CSF diversion [<xref ref-type="bibr" rid="scirp.77014-ref3">3</xref>] . Patients with meningitis and pseudomeningocele have higher risk of shunt requirement [<xref ref-type="bibr" rid="scirp.77014-ref7">7</xref>] .</p><p>VP shunt is still an option to treat hydrocephalus preoperatively. It can be done in those patients who are in poor neurological state as a result of delayed diagnosis and advanced disease. Papilledema responds well to VP shunt. It significantly reduces the overall morbidity and mortality. It may result in shunt infection and malfunction [<xref ref-type="bibr" rid="scirp.77014-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref19">19</xref>] . However, it can cause upward herniation, tumor hemorrhage and peritoneal seeding. It will be difficult to make a plane between the tumor and adjacent normal brain and brain stem during tumor surgery [<xref ref-type="bibr" rid="scirp.77014-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref20">20</xref>] . Preoperative VP shunt requirement varied from 29% - 43.1% after using different surgical options for the treatment of hydrocephalus depending on the presentation [<xref ref-type="bibr" rid="scirp.77014-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref21">21</xref>] . It also depends on the policy of the center.</p><p>The use of preoperative ETV is an effective, feasible and safe procedure [<xref ref-type="bibr" rid="scirp.77014-ref22">22</xref>] . It is helpful in immediate and long term control of hydrocephalus [<xref ref-type="bibr" rid="scirp.77014-ref10">10</xref>] . It eliminates the risk of CSF infection related to EVD and avoids the complications of VP shunt like infection and malfunction. In developing countries where the presentation is late, ETV is recommendable option due to large ventricles [<xref ref-type="bibr" rid="scirp.77014-ref22">22</xref>] . However, ETV cannot always prevent postoperative hydrocephalus in all cases of posterior fossa tumors. The use of postoperative VP shunt is the alternative [<xref ref-type="bibr" rid="scirp.77014-ref10">10</xref>] . VP shunt was required in 6% of the patients after ETV for hydrocephalus related to posterior fossa tumor [<xref ref-type="bibr" rid="scirp.77014-ref20">20</xref>] .</p><p>EVD placement is one of the most commonly performed neurosurgical procedures. It is an effective alternate method to insertion of preoperative shunts [<xref ref-type="bibr" rid="scirp.77014-ref23">23</xref>] . It can be inserted preoperatively or intraoperatively. Preoperative EVD insertion is indicated in those patients who present in emergency with symptoms and signs of raised ICP. Care should be taken not to drain CSF quickly. ICP is usually high and is more than 30 cm of water in most of the cases [<xref ref-type="bibr" rid="scirp.77014-ref24">24</xref>] . The goal is to do slow controlled sustained decompression of ICP. It is one of the advantages as compared to the shunt where pressure of the valve is predetermined. One can adjust the level of EVD depending on the ICP. It is a live saving emergency procedure. It controls ICP before, during and after surgery [<xref ref-type="bibr" rid="scirp.77014-ref25">25</xref>] . It allows the drainage of blood and debris from CSF after tumor surgery [<xref ref-type="bibr" rid="scirp.77014-ref19">19</xref>] . Moreover, it provides smooth postoperative course. It decreases the possibility of aseptic meningitis and postoperative shunts [<xref ref-type="bibr" rid="scirp.77014-ref23">23</xref>] . It also prevents CSF leak and helps in wound healing by keeping the surgical wound dry [<xref ref-type="bibr" rid="scirp.77014-ref19">19</xref>] . However, it may result in tumoral hemorrhage and upward herniation [<xref ref-type="bibr" rid="scirp.77014-ref10">10</xref>] . The main issue related to EVD is CSF infection. It can be left safely, as long as needed, provided that meticulous care is taken for EVD insertion and nursing. EVD duration seems to have no effect on incidence of infection [<xref ref-type="bibr" rid="scirp.77014-ref26">26</xref>] . Infection rate of 7% - 10% was noted per procedure [<xref ref-type="bibr" rid="scirp.77014-ref27">27</xref>] .<sup> </sup>More than five days of drainage seems to raise concern for infection risk, though the weight of evidence shows long term drainage is safe and the routine catheter changes have led to higher not lower infection rates [<xref ref-type="bibr" rid="scirp.77014-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref29">29</xref>] .<sup> </sup>Tunneling the catheter from insertion site as far as possible is preferred. Prophylactic systemic antibiotic use for the duration of drainage has shown little benefit. Antibiotic-impregnated EVD reduces the chance of catheter related infections [<xref ref-type="bibr" rid="scirp.77014-ref30">30</xref>] . Overall, meticulous technique at the time of insertion, cautious wound care, and aseptic technique during CSF sampling are essential to reduce infection rates. In our study, EVD related CSF infection was seen postoperatively in three patients in both groups. Only one patient had infection preoperatively in group B. None of the patient had infection preoperatively in group A. Overall infection rate was 18.4%. Gopalakrishnan et al. stated that children who underwent intraoperative EVD insertion had shunt rate of 39.6% compared with 16.7% of those who did not have an EVD [<xref ref-type="bibr" rid="scirp.77014-ref7">7</xref>] .<sup> </sup>The postoperative VP shunt was required in 6.1-19% the patients who had intraoperative EVD [<xref ref-type="bibr" rid="scirp.77014-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref25">25</xref>] . Some advocate that there is no association of EVD with the need of postoperative CSF diversion [<xref ref-type="bibr" rid="scirp.77014-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref24">24</xref>] .<sup> </sup>While others had concluded that EVD dependence is a reliable predictor for permanent CSF diversion [<xref ref-type="bibr" rid="scirp.77014-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref32">32</xref>] . In one study, 95.2% of the patients had symptomatic hydrocephalus but postoperative VP shunt was required in 29.8% of the patients. These were managed with either intraoperative EVD or without CSF diversion [<xref ref-type="bibr" rid="scirp.77014-ref7">7</xref>] . Most of the surgeons believe that eventually one third of the patients will require postoperative CSF diversion. Rate of VP shunt insertion was 30% - 38.7% in different studies [<xref ref-type="bibr" rid="scirp.77014-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.77014-ref19">19</xref>] .<sup> </sup>Schmid inserted EVD 2 - 5 days before definitive posterior fossa tumor surgery. His shunt free rate in children was 83% and infection rate was 4.9%. A shunt was inserted only if the CSF pathways remained obstructed after tumor removal [<xref ref-type="bibr" rid="scirp.77014-ref24">24</xref>] . With this regimen, shunt insertion rate can be lowered down with the risk of infection. We did not find any study in the literature that suggests that duration of preoperative EVD has any effect on postoperative permanent CSF diversion. In our study, not only our patients were symptomatic as they presented with signs and symptoms of raised ICP and they all were in need for emergency EVD insertion to relieve the pressure. Eventually, VP shunt was required in nine patients with 31.25% of the patients in group A and 18.18% of the patients in group B. These numbers may suggest that the longer duration of preoperative EVD can reduce the need for permanent CSF diversion postoperatively. But statistically these numbers have no significance (p value = 0.35). Overall, our shunt free rate was 76.3%.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Still there is no agreement on the management of hydrocephalus due to posterior fossa tumors. It depends on surgeon’s preferences, case to case variations and departmental policies and guidelines. All patients had severe hydrocephalus at presentation in our study. While using single modality for the management of hydrocephalus, permanent shunt insertion rate was comparably low. However, there is no effect of preoperative duration of EVD in determining the requirement of postoperative VP shunt.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We are grateful to Mr. Anhar Ullah from department of cardiac sciences, College of Medicine, King Saud University, Riyadh, Saudi Arabia, for his support and work in analyzing the data.</p></sec><sec id="s7"><title>Cite this paper</title><p>Ghani, E., AlBanyan, A., Sabbagh, A. and Ahmad, M. (2017) Duration of Preoperative External Ventricular Drain in Pediatric Posterior Fossa Tumors―Does It Matter? Open Journal of Ped- iatrics, 7, 86-97. https://doi.org/10.4236/ojped.2017.72012</p></sec></body><back><ref-list><title>References</title><ref id="scirp.77014-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cohen-Gadol, A.A. and Spencer, D.D. (2004) Inauguration of Pediatric Neurosurgery by Harvey W. Cushing: His Contributions to the Surgery of Posterior Fossa Tumors in Children. Historical Vignette. Journal of Neurosurgery, 100, 225-231.</mixed-citation></ref><ref id="scirp.77014-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Cushing, H. (1930) Experience with the Cerebellar Medulloblastoma: Critical Review. Acta pathologica et microbiologica Scandinavica, 7, 1-86.  
https://doi.org/10.1111/j.1600-0463.1930.tb06503.x</mixed-citation></ref><ref id="scirp.77014-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Due-Tonnessen, B.J. and Helseth, E. (2007) Management of Hydrocephalus in Children with Posterior Fossa Tumors: Role of Tumor Surgery. Pediatric Neurosurgery, 43, 92-96. https://doi.org/10.1159/000098379</mixed-citation></ref><ref id="scirp.77014-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Foreman, P., McClugage, S. III, Naftel, R., Griessenauer, C.J., Ditty, B.J., Agee, B.S., et al. (2013) Validation and Modification of a Predictive Model of Postresection Hydrocephalus in Pediatric Patients with Posterior Fossa Tumors. Journal of Neurosurgery: Pediatrics, 12, 220-226. https://doi.org/10.3171/2013.5.PEDS1371</mixed-citation></ref><ref id="scirp.77014-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kulkarni, A.V., Piscione, J., Shams, I. and Bouffet, E. (2013) Long Term Quality of Life in Children Treated for Posterior Fossa Brain Tumors. Journal of Neurosurgery: Pediatrics, 12, 235-240. https://doi.org/10.3171/2013.6.PEDS12535</mixed-citation></ref><ref id="scirp.77014-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Riva-Cambrin, J., Detsky, A.S., Lamberti-Pasculli, M., Sargent, M.A., Armstrong, D., Moineddin, R., et al. (2009) Predicting Postresection Hydrocephalus in Pediatric Patients with Posterior Fossa Tumors. Journal of Neurosurgery: Pediatrics, 3, 378-385. https://doi.org/10.3171/2009.1.PEDS08298</mixed-citation></ref><ref id="scirp.77014-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gopalakrishnan, C.V., Dhakoji, A., Menon, G. and Nair, S. (2012) Factors Predicting the Need for Cerebrospinal Fluid Diversion Following Posterior Fossa Tumor Surgery in Children. Pediatric Neurosurgery, 48, 93-101.  
https://doi.org/10.1159/000343009</mixed-citation></ref><ref id="scirp.77014-ref8"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abou-Madawi</surname><given-names> A. </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>VP-Shunt Requirement in Patients with Posterior Fossa Tumors</article-title><source> Suez Canal Univ Med J</source><volume> 10</volume>,<fpage> 121</fpage>-<lpage>128</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.77014-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Santos de Oliveira, R., Barros, J.C.E., Valera, E.T., and Machado, H.R. (2008) Hydrocephalus in Posterior Fossa Tumors in Children. Are there Factors that Determine a Need for Permanent Cerebrospinal Fluid Diversion? Child’s Nervous System, 24, 1397-1403. https://doi.org/10.1007/s00381-008-0649-x</mixed-citation></ref><ref id="scirp.77014-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nagy, M.R. and El-Beltagy, M.A. (2012) Cerebrospinal Fluid Diversion Procedures in Children with Posterior Fossa Tumors: Ventriculoperitoneal Shunts versus Endoscopic Third Ventriculostomy versus External Ventricular Drainage. Medical Journal of Cairo University, 80, 249-254.</mixed-citation></ref><ref id="scirp.77014-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Schijman, E., Peter, J.C., Rekate, H.L., Sgouros, S. and Wong, T.T. (2004) Management of Hydrocephalus in Posterior Fossa Tumors: How, What, When? Child’s Nervous System, 20, 192-194. https://doi.org/10.1007/s00381-003-0900-4</mixed-citation></ref><ref id="scirp.77014-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Abraham, J. and Chandy, J. (1963) Ventriculo-Atrial Shunt in the Management of Posterior Fossa Tumors. Preliminary Report. Journal of Neurosurgery, 20, 252-253.  
https://doi.org/10.3171/jns.1963.20.3.0252</mixed-citation></ref><ref id="scirp.77014-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Albright, L. and Reigel, D.H. (1977) Management of Hydrocephalus Secondary to Posterior Fossa Tumors. Journal of Neurosurgery, 46, 52-55.  
https://doi.org/10.3171/jns.1977.46.1.0052</mixed-citation></ref><ref id="scirp.77014-ref14"><label>14</label><mixed-citation publication-type="book" xlink:type="simple">McLaurin, R.L. (1985) On the Use of Precraniotomy Shunting in the Management of Posterior Fossa Tumors in Children: A Cooperative Study. In: Chapman, P.H., Ed., Concepts in Pediatric Neurosurgery, Vol. 6, Karger, New York, 1-5.</mixed-citation></ref><ref id="scirp.77014-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cushing, H. (1931) Experiences with the Cerebellar Astrocytoma. A Clinical Review of Seventy-Six Cases. Surgery, Gynecology &amp; Obstetrics, 52, 129-204.</mixed-citation></ref><ref id="scirp.77014-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Goel, A. (1993) Whether Preoperative Shunts for Posterior Fossa Tumors? British Journal of Neurosurgery, 7, 395-399. https://doi.org/10.3109/02688699309103494</mixed-citation></ref><ref id="scirp.77014-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, C., Wu, X., Lin, Z., Wang, C. and Kang, D. (2013) External Drainage with an Ommaya Reservoir for Perioperative Hydrocephalus in Children with Posterior Fossa Tumors. Child’s Nervous System, 29, 1293-1297. 
https://doi.org/10.1007/s00381-013-2078-8</mixed-citation></ref><ref id="scirp.77014-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Islam, M.R., Islam, K.M.T., Hossain, M., Rashid, M.H., Dhakhal, S., Khair, A., et al. (2011) Clinical Outcome of Posterior Fossa Tumor Surgery without Preoperative Ventriculoperitoneal Shunt. Bangladesh Journal of Medicine, 40, 43-47.</mixed-citation></ref><ref id="scirp.77014-ref19"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ghani</surname><given-names> E.</given-names></name>,<name name-style="western"><surname> Zaidi</surname><given-names> G.I.</given-names></name>,<name name-style="western"><surname> Nadeem</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Rehman</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Noman</surname><given-names> M.A. and Khaleeq-Uz-Zaman. </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>Role of Cerebrospinal Fluid Diversion in Posterior Fossa Tumor Surgery</article-title><source> Journal of the College of Physicians and Surgeons</source><volume> 13</volume>,<fpage> 333</fpage>-<lpage>336</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.77014-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sainte-Rose, C., Cinalli, G., Roux, F.E., Maixner, W., Chumas, P.D., Mansour, M., et al. (2001) Management of Hydrocephalus in Pediatric Patients with Posterior Fossa Tumors: The Role of Endoscopic Third Ventriculostomy. Journal of Neurosurgery, 95, 791-797. https://doi.org/10.3171/jns.2001.95.5.0791</mixed-citation></ref><ref id="scirp.77014-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Dias, M.S. and Albright, A.L. (1989) Management of Hydrocephalus Complicating Childhood Posterior Fossa Tumors. Pediatric Neurosurgery, 15, 283-290. 
https://doi.org/10.1159/000120484</mixed-citation></ref><ref id="scirp.77014-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bhatia, R., Tahir, M. and Chandler, C.L. (2009) The Management of Hydrocephalus in Children with Posterior Fossa Tumors: The Role of Pre-Resectional Endoscopic Third Ventriculostomy. Pediatric Neurosurgery, 45, 186-191.  
https://doi.org/10.1159/000222668</mixed-citation></ref><ref id="scirp.77014-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Rappaport, Z.H. and Shalit, M.N. (1989) Perioperative External Ventricular Drainage in Obstructive Hydrocephalus Secondary to Infratentorial Brain Tumors. Acta Neurochirurgic, 96, 118-121. https://doi.org/10.1007/BF01456169</mixed-citation></ref><ref id="scirp.77014-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Schmid, U.D. and Seiler, R.W. (1986) Management of Obstructive Hydrocephalus Secondary to Posterior Fossa Tumors by Steroids and Subcutaneous Ventricular Catheter Reservoir. Journal of Neurosurgery, 65, 649-653.  
https://doi.org/10.3171/jns.1986.65.5.0649</mixed-citation></ref><ref id="scirp.77014-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Habib, H.A.M. (2013) Intraoperative Precautionary Insertion of External Ventricular Drainage Catheters in Posterior Fossa Tumors Presenting with Hydrocephalus. Alexandria Journal of Medicine, 50, 333-340.  
https://doi.org/10.1016/j.ajme.2013.11.001</mixed-citation></ref><ref id="scirp.77014-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Korinek, A.M., Reina, M., Boch, A.L., Rivera, A.O., De Bels, D. and Puybasset, L. (2005) Prevention of External Ventricular Drain-Related Ventriculitis. Acta Neurochirurgica, 147, 39-45. https://doi.org/10.1007/s00701-004-0416-z</mixed-citation></ref><ref id="scirp.77014-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Kulkarni, A.V., Drake, J.M. and Lambert-Pasculli, M. (2001) Cerebrospinal Fluid Shunt Infection: A Prospective Study of Risk Factors. Journal of Neurosurgery, 94, 195-201. https://doi.org/10.3171/jns.2001.94.2.0195</mixed-citation></ref><ref id="scirp.77014-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Lo, C.H., Spelman, D., Bailey, M. (2007) External Ventricular Drain Infections Are Independent of Drain Duration: An Argument against Elective Revision. Journal of Neurosurgery, 106, 378-383. https://doi.org/10.3171/jns.2007.106.3.378</mixed-citation></ref><ref id="scirp.77014-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Dasic, D., Hanna, S.J., Bojanic S. (2006) External Ventricular Drain Infection: The Effect of a Strict Protocol on Infection Rates and a Review of the Literature. British Journal of Neurosurgery, 20, 296-300. https://doi.org/10.1080/02688690600999901</mixed-citation></ref><ref id="scirp.77014-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Tamburrini, G., Massimi, L., Caldarelli, M. and Di Rocco, C. (2008) Antibiotic Impregnated External Ventricular Drainage and Third Ventriculostomy in the Management of Hydrocephalus Associated Posterior Cranial Fossa Tumors. Acta Neurochirurgica, 150, 1049-1055. https://doi.org/10.1007/s00701-008-0022-6</mixed-citation></ref><ref id="scirp.77014-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Culley, D.J., Berger, M.S., Shaw, D. (1994) An Analysis of Factors Determining the Need for Ventriculoperitoneal Shunts after Posterior Fossa Tumor Surgery in Children. Neurosurgery, 34, 402-408.  
https://doi.org/10.1227/00006123-199403000-00003</mixed-citation></ref><ref id="scirp.77014-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Serlo, W., Fernell, E., Heikkinen, E., Anderson, H. and von Wendt, L. (1990) Functions and Complications of Shunts in Different Etiologies of Childhood Hydrocephalus. Child’s Nervous System, 6, 92-94. https://doi.org/10.1007/BF00307928</mixed-citation></ref></ref-list></back></article>